Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q7UD
|
|||
| Former ID |
DNC008718
|
|||
| Drug Name |
ABT-888
|
|||
| Synonyms |
Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1], [2], [3] | |
| Epithelial ovarian cancer [ICD-11: 2B5D; ICD-9: 183] | Phase 3 | [4] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [3] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [3] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [4] | ||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C13H18Cl2N4O
|
|||
| Canonical SMILES |
CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
|
|||
| InChI |
1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
|
|||
| InChIKey |
DSBSVDCHFMEYBX-FFXKMJQXSA-N
|
|||
| CAS Number |
CAS 912445-05-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
17418828, 23919521, 36457782, 48431542, 53786540, 57298845, 78845658, 85742017, 93581011, 99432361, 99443703, 103628124, 123051081, 124490432, 124756927, 125163734, 126522682, 126626210, 126661310, 126665801, 126731194, 131271125, 131465098, 134223378, 134345923, 135251923, 136367452, 137275905, 137517732, 138192110, 152090859, 152258095, 152344520, 160646934, 160968315, 162011690, 162202719, 163776182, 163907937, 164041817, 164194024, 164339419, 174531428, 178103989, 184816212, 194943753, 198953538, 198994026, 208265497, 212343015
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase (PARP) | Target Info | Modulator | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417). | |||
| REF 2 | ClinicalTrials.gov (NCT02163694) A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.